Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
How Should Medical Affairs Engage on Social Media
Summary
In this episode, Tom Caravela and Sarah Snyder delve into the vital role of social media for Medical Science Liaisons (MSLs). They discuss its evolution in medical affairs, platforms for professionals, and the benefits of social engagement for relationship building. Sarah offers insights on balancing personal and professional brands, best practices for engaging with healthcare professionals, and staying updated on medical advancements. They also cover social media pitfalls, thought leadership, compliance considerations, and future trends in digital tools and AI's impact on MSL roles, concluding with a look at evolving digital opinion leaders.
Key Points
- Understanding and engaging with HCPs and KOLs on social media is essential for MSLs in today's digital world, as it helps speed up relationship building and keeps them informed about current trends and discussions in their field.
- MSLs should focus on social listening and following key hashtags, especially during conferences, to stay updated on the latest scientific advancements and to see where their KOLs are active without necessarily having to post or comment themselves.
- It's crucial for MSLs to maintain a clear separation between their personal and professional social media accounts, adhere strictly to their company's compliance guidelines, and avoid engaging in debates or commenting on product-specific information to mitigate risks.
Medical Science Liaisons, social media engagement, healthcare professionals, digital opinion leaders, compliance in medical affairs
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary